Decoy Therapeutics Inc. Market Cap ($678.12K)
Market Cap & Net Worth: Decoy Therapeutics Inc. (DCOY)
Decoy Therapeutics Inc. market cap. Decoy Therapeutics Inc. (NASDAQ:DCOY) has a market capitalization of $678.12K ($678.12K) as of November 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #30905 globally and #6277 in its home market, demonstrating a 6.70% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Decoy Therapeutics Inc.'s stock price $1.04 by its total outstanding shares 655185 (655.18K). Also see DCOY cash generation efficiency for how efficiently the company converts equity into cash flow.
Decoy Therapeutics Inc. Market Cap History (2026–2026)
Decoy Therapeutics Inc. market cap history from 2026 to 2026. Data shows growth from $678.12K to $678.12K (0.00% CAGR). Check Decoy Therapeutics Inc. share price for real-time trading data and today's change.
Decoy Therapeutics Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Decoy Therapeutics Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore DCOY shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of DCOY by Market Capitalization
Companies near Decoy Therapeutics Inc. in the global market cap rankings as of November 3, 2026. Also see Decoy Therapeutics Inc. asset portfolio for a full breakdown of the balance sheet.
Key companies related to Decoy Therapeutics Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of Decoy Therapeutics Inc. (2026–2026)
Market capitalization of Decoy Therapeutics Inc. from 2026 to today. Between 2026 and today, Decoy Therapeutics Inc.'s market cap moved from $678.12K to $ 678.12K, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $678.12K | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Decoy Therapeutics Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $678.12K USD |
| MoneyControl | $678.12K USD |
| MarketWatch | $678.12K USD |
| marketcap.company | $678.12K USD |
| Reuters | $678.12K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Decoy Therapeutics Inc.
Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools. The company's IMP3ACT platform leverage… Read more